Aripiprazole and Ropinirole Treatment for Cocaine Dependence: Evidence from a Pilot Study

Meini, Milo; Moncini, M.; Cecconi, D.; Cellesi, Valerio; Biasci, L; Simoni, G; Ameglio, Matteo; Pellegrini, M.; Forgione, Rocco Nicola; Rucci, Paola

doi:10.2174/138161211796150783

Cited by 27 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…L-DOPA showed beneficial effects on the number of cocaine-negative urine samples, but only in combination with CM + CBT + VBRT, suggesting that L-DOPA pharmacotherapy may be an option for cocaine dependence when combined with behavioral therapies (Schmitz et al, 2008). Ropinirole acted as, albeit a weak, reinforcer in nonhuman primates (Freeman, Heal, McCreary, & Woolverton, 2012), which partly supports clinical data, suggesting that ropinirole marginally reduced craving in humans (Meini et al, 2012) and reduced the subjective intensity for the "cocaine rush" (Maremmani et al, 2011). Treatment with another dopamine D 2 agonist, pramipexole, caused perseverated responding in a reversal learning task, which was associated with stimulant dependence, rather than compulsive measures, suggesting additional efficacy for the potential treatment of SUD (Ersche et al, 2011).…”

Section: L-dopasupporting

confidence: 58%

Psychostimulants

McCreary

Müller

Filip

2015

International Review of Neurobiology

View full text Add to dashboard Cite

Section: L-dopasupporting

confidence: 58%

Psychostimulants

McCreary

Müller

Filip

2015

International Review of Neurobiology

View full text Add to dashboard Cite

“…Recent reports demonstrate that ropinirole is able to reduce the subjective reinforcing effect of cocaine in humans [96], [97]; moreover Hoefer et al [51] showed that ropinirole was able to counteract the reward deficit in methamphetamine withdrawal in rats, supporting the hypothesis that activating, rather than blocking, the DAergic system could help attenuating drug seeking behaviour [98]. Additional studies need to be undertaken to evaluate ropinirole efficacy in alcohol relapse in order to suggest its administration as a pharmacological aid in controlling the chronic relapsing nature of alcohol abuse.…”

Section: Discussionmentioning

confidence: 99%

Involvement of Dopamine D2 Receptors in Addictive-Like Behaviour for Acetaldehyde

et al. 2014

View full text Add to dashboard Cite

Acetaldehyde, the first metabolite of ethanol, is active in the central nervous system, where it exerts motivational properties. Acetaldehyde is able to induce drinking behaviour in operant-conflict paradigms that resemble the core features of the addictive phenotype: drug-intake acquisition and maintenance, drug-seeking, relapse and drug use despite negative consequences. Since acetaldehyde directly stimulates dopamine neuronal firing in the mesolimbic system, the aim of this study was the investigation of dopamine D2-receptors' role in the onset of the operant drinking behaviour for acetaldehyde in different functional stages, by the administration of two different D2-receptor agonists, quinpirole and ropinirole. Our results show that acetaldehyde was able to induce and maintain a drug-taking behaviour, displaying an escalation during training, and a reinstatement behaviour after 1-week forced abstinence. Acetaldehyde operant drinking behaviour involved D2-receptor signalling: in particular, quinpirole administration at 0.03 mg/kg, induced a significant decrease in the number of lever presses both in extinction and in relapse. Ropinirole, administered at 0.03 mg/kg during extinction, did not produce any modification but, when administered during abstinence, induced a strong decrease in acetaldehyde intake in the following relapse session. Taken together, our data suggest that acetaldehyde exerts its own motivational properties, involving the dopaminergic transmission: indeed, activation of pre-synaptic D2-receptors by quinpirole, during extinction and relapse, negatively affects operant behaviour for acetaldehyde, likely decreasing acetaldehyde-induced dopamine release. The activation of post-synaptic D2-receptors by ropinirole, during abstinence, decreases the motivation to the consecutive reinstatement of acetaldehyde drinking behaviour, likely counteracting the reduction in the dopaminergic tone typical of withdrawal. These data further strengthen the evidence that acetaldehyde may play a crucial role as mediator of ethanol's central effects.

show abstract

“…P = primary outcome; S = secondary outcome;* significant at P < 0.05;** significant at P < 0.01;*** significant at P < 0.001;RaR = rate ratio; RR = relative risk; OR = odds ratio; MD = mean difference;Ω range of population SD reflects the CI of the expected effect size;α range of population SD based on opinion on a viable effect; a one‐directional relationship was assumed in all instances; Based on:a 31;b 32;c 33;d 34;e 35;f 36;g values specified in the sample size calculation;h 37;i 38;j 39;k 40;l 41;m 42;n 43;o 44;p 45;q 46;r 47;s 48;t 49;u 50;v 51;w 52;z 53;y values specified in the sample size calculation.HAMD = Hamilton Rating Scale for Depression; p.p.m. = parts per million.…”

Section: Methodsmentioning

confidence: 99%

Using Bayes factors for testing hypotheses about intervention effectiveness in addictions research

et al. 2016

View full text Add to dashboard Cite

Background and AimsIt has been proposed that more use should be made of Bayes factors in hypothesis testing in addiction research. Bayes factors are the ratios of the likelihood of a specified hypothesis (e.g. an intervention effect within a given range) to another hypothesis (e.g. no effect). They are particularly important for differentiating lack of strong evidence for an effect and evidence for lack of an effect. This paper reviewed randomized trials reported in Addiction between January and June 2013 to assess how far Bayes factors might improve the interpretation of the data.MethodsSeventy‐five effect sizes and their standard errors were extracted from 12 trials. Seventy‐three per cent (n = 55) of these were non‐significant (i.e. P > 0.05). For each non‐significant finding a Bayes factor was calculated using a population effect derived from previous research. In sensitivity analyses, a further two Bayes factors were calculated assuming clinically meaningful and plausible ranges around this population effect.ResultsTwenty per cent (n = 11) of the non‐significant Bayes factors were < ⅓ and 3.6% (n = 2) were > 3. The other 76.4% (n = 42) of Bayes factors were between ⅓ and 3. Of these, 26 were in the direction of there being an effect (Bayes factor > 1 and < 3); 12 tended to favour the hypothesis of no effect (Bayes factor < 1 and > ⅓); and for four there was no evidence either way (Bayes factor = 1). In sensitivity analyses, 13.3% of Bayes Factors were < ⅓ (n = 20), 62.7% (n = 94) were between ⅓ and 3 and 24.0% (n = 36) were > 3, showing good concordance with the main results.ConclusionsUse of Bayes factors when analysing data from randomized trials of interventions in addiction research can provide important information that would lead to more precise conclusions than are obtained typically using currently prevailing methods.

show abstract

Aripiprazole and Ropinirole Treatment for Cocaine Dependence: Evidence from a Pilot Study

Abstract: Our pilot study indicates that cocaine craving decreases with both aripiprazole and ropinirole treatment but aripiprazole is more efficacious in reducing cocaine use.

Cited by 27 publications

References 42 publications

Psychostimulants

Psychostimulants

Involvement of Dopamine D2 Receptors in Addictive-Like Behaviour for Acetaldehyde

Using Bayes factors for testing hypotheses about intervention effectiveness in addictions research

Contact Info

Product

Resources

About